Effect of PRP as Therapy for Shoulder Osteoarthritis

NCT ID: NCT05043493

Last Updated: 2021-09-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

91 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-01

Study Completion Date

2021-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with shoulder osteoarthritis are suffering from pain and disabilities which lead to difficulties in life. The presence of platelet-rich plasma as regenerative therapy which helps in healing of damaged tissues like ligaments and joint might be of great benefit in managing such conditions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary and secondary osteoarthritis of the shoulder occurs due to destruction of the articular surface of the humeral head and glenoid , Patient mainly presented with pain and decreases in the range of motion .

Treatment of shoulder osteoarthritis is often controversial and is typically based on the patient's age, the severity of symptoms, and level of activity, radiographic findings, and medical comorbidities.

The new era of management include regenerative therapy ,Platelet-rich plasma (PRP) is one of the regenerative therapy that prove its effect as injections of a concentration of a patient's own platelets to accelerate the healing of injured tendons, ligaments, muscles and joints.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Shoulder Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Injection (study) group

This group will receive platelet rich plasma (PRP) injection

Group Type ACTIVE_COMPARATOR

Injection in the intraarticular space of glenohumeral joint

Intervention Type PROCEDURE

U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)

Control group

This group will receive normal saline (NS) injection

Group Type PLACEBO_COMPARATOR

Injection in the intraarticular space of glenohumeral joint

Intervention Type PROCEDURE

U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Injection in the intraarticular space of glenohumeral joint

U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient's age: From 21 years.
* Acute symptoms on a background of at least a 3-month history of chronic pain or swelling of the shoulder joint with radiological confirmed (X-ray or MRI)
* Mild or moderate osteoarthritis of the shoulder joint according to The Samilson-Prieto classification.
* Numerical Rating Scale for pain scores greater than five on a 10 scale

Exclusion Criteria

* Under 21 years of age
* Severe osteoarthritis according to The Samilson-Prieto classification. (Figure 1)
* Neuropsychiatric disorders.
* Immunocompromised patients.
* Active infection or malignancy at the joint.
* Pregnancy and breastfeeding.
* Patients may have thrombocytopenia, bleeding disorders, or on anticoagulant therapy.
* Shoulder surgery within 3 months or inflammatory arthritis; previous infection of the shoulder joint.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amr Abd Elfatah, proffeseor

Role: STUDY_DIRECTOR

department of anesthesia ,ICU, and pain management ASU

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ainshams University

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ASU 000017585

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Shoulder RFA Pilot Study
NCT06039345 RECRUITING